May 24, 2024
Diabetic Kidney Disease

Diabetic Kidney Disease Market Witness Growth due to Rising Prevalence of Diabetes

Market Overview
Diabetic kidney disease, also known as diabetic nephropathy, is a condition in which the kidneys are damaged either due to type 1 or type 2 diabetes. Exposure to high blood sugar levels for a long duration leads to deterioration of kidney function and impact normal renal functioning. The key symptoms include proteinuria, impaired renal function and loss of kidney function over time. Treatment options for diabetic kidney disease include controlling blood sugar and blood pressure levels through medications and dialysis.

The global diabetic kidney disease market is estimated to be valued at US$ 4.21 Bn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in The Diabetic Kidney Disease Market are AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb, GSK, Novo Nordisk, Eli Lilly and Company, Merck & Co., Sanofi, AbbVie, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Lupin, Aurobindo Pharma, Takeda Pharmaceutical Company Limited, Biogen, Vertex Pharmaceuticals Incorporated. The key opportunities in the market include increasing awareness among patients and healthcare providers about the condition and its management. Globally, there is a rise in diabetes prevalence worldwide which will drive the growth of diabetic kidney disease market across regions.

Market drivers
The rising prevalence of diabetes is the major driver for the growth of diabetic kidney disease market. As per the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021 worldwide and the number is expected to rise to 643 million by 2030 and 783 million by 2045. Exposure to diabetes for prolonged duration significantly increases the risk of developing chronic kidney disease. Thus, growing diabetic population directly impacts the increase in diabetic kidney disease cases, positively influence the market growth.

PEST Analysis
Political: Increased government investments and favorable reimbursement policies for diabetic kidney disease treatment is influencing the market growth positively.

Economic: Rising healthcare expenditures along with growing per capita income is boosting the market. However, high treatment costs due to expensive drugs remains a challenge.

Social: Growing prevalence of diabetes and obesity leading to increased risk of kidney diseases is a major factor. Also, rising health awareness is benefiting the market.

Technological: Advancements in drug delivery systems, drug development process and diagnostic technologies are helping improve treatment outcomes and revolutionizing patient care. Development of combination therapies and personalized treatment approaches are further fueling the market growth.

Geographical regions with high market concentration
North America dominates the diabetic kidney disease market in terms of value owing to high prevalence of diabetes, rising geriatric population, growing healthcare expenditures and presence of major players in the region. The United States holds the largest share within North America due to well established reimbursement policies and healthcare infrastructure.

Europe is another prominent market driven by rising prevalence of chronic kidney diseases and diabetes. Government initiatives to expand healthcare access and increase public awareness about these conditions also support market growth in Europe.

Fastest growing region
Asia Pacific region is poised to witness the highest growth over the forecast period attributed to increasing diabetic population due to rapid urbanization, lifestyle changes and growing medical tourism. Rising disposable incomes, growing healthcare infrastructure and expanding base of private hospitals offering advanced treatment options are also fueling market growth in Asia Pacific region.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it